Methadone Doses
Primary
· 3 months prior to enrollment
Percentage of Missed Methadone Doses, Range 0 - 100%, Lower percentages mean better outcome.
| Group | Value | 95% CI |
|---|---|---|
| Intervention Arm | 4.58 | ± 4.58 |
Last reviewed · How we verify
NCT05803603: SASH
Social Work Assistance and Stipends for Housing (SASH)
Completed
NA
Results posted
Last updated 18 April 2025
What this trial tests
NA trial testing Stipend and Social Work Supports in Opioid-Related Disorders in 8 participants. Completed in 1 January 2024.
Timeline
1 December 2022
Primary endpoint
1 January 2024
1 January 2024
1 January 2024
Quick facts
| Lead sponsor | University of Maryland, Baltimore |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 8 |
| Start date | 1 December 2022 |
| Primary completion | 1 January 2024 |
| Estimated completion | 1 January 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Stipend and Social Work Supports
Conditions studied
- Opioid-Related Disorders — all drugs for Opioid-Related Disorders →
- Housing Problems — all drugs for Housing Problems →
Sponsor
University of Maryland, Baltimore
Who can join
Adults 18 to 80, any sex, with Opioid-Related Disorders or Housing Problems. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Methadone Doses
Primary
· 3-6 months post enrollment
Percentage of Missed Methadone Doses, Range 0 - 100%, Lower percentages mean better outcome.
| Group | Value | 95% CI |
|---|---|---|
| Intervention Arm | 7.47 | ± 7.94 |
Methadone Doses
Primary
· 9-12 months post enrollment.
Percentage of Missed Methadone Doses, Range 0 - 100%, Lower percentages mean better outcome.
| Group | Value | 95% CI |
|---|---|---|
| Intervention Arm | 34.11 | ± 32.11 |
OUD Checklist Scores
Primary
· Baseline
Scores on the Diagnostic and Statistical Manual V OUD checklist. Range 0 - 13. Higher scores mean worse outcome with 2-3 as mild severity, 4-5 moderate severity and 6 or more as severe.
| Group | Value | 95% CI |
|---|---|---|
| Intervention Arm | 8.25 | ± 7.4 |
OUD Checklist Scores
Primary
· 6 months
Scores on the Diagnostic and Statistical Manual V OUD checklist. Range 0 - 13. Higher scores mean worse outcome with 2-3 as mild severity, 4-5 moderate severity and 6 or more as severe.
| Group | Value | 95% CI |
|---|---|---|
| Intervention Arm | 7.4 | ± 4.4 |
OUD Checklist Scores
Primary
· 12 months
Scores on the Diagnostic and Statistical Manual V OUD checklist. Range 0 - 13. Higher scores mean worse outcome with 2-3 as mild severity, 4-5 moderate severity and 6 or more as severe.
| Group | Value | 95% CI |
|---|---|---|
| Intervention Arm | 7.2 | ± 5.3 |
Urine Toxicology Tests
Primary
· Three months prior to enrollment
Detection of positive urine toxicology tests collected from chart reviews. Values are positive or negative for controlled substances. Positive test the worse outcome
| Group | Value | 95% CI |
|---|---|---|
| Intervention Arm | 7 |
Urine Toxicology Tests
Primary
· Month 1
Detection of positive urine toxicology tests collected from chart reviews. Values are positive or negative for controlled substances. Positive test the worse outcome
| Group | Value | 95% CI |
|---|---|---|
| Intervention Arm | 5 |
Urine Toxicology Tests
Primary
· Month 2
Detection of positive urine toxicology tests collected from chart reviews. Values are positive or negative for controlled substances. Positive test the worse outcome
| Group | Value | 95% CI |
|---|---|---|
| Intervention Arm | 4 |
Urine Toxicology Tests
Primary
· Month 3
Detection of positive urine toxicology tests collected from chart reviews. Values are positive or negative for controlled substances. Positive test the worse outcome
| Group | Value | 95% CI |
|---|---|---|
| Intervention Arm | 5 |
Urine Toxicology Tests
Primary
· Month 4
Detection of positive urine toxicology tests collected from chart reviews. Values are positive or negative for controlled substances. Positive test the worse outcome
| Group | Value | 95% CI |
|---|---|---|
| Intervention Arm | 5 |
Urine Toxicology Tests
Primary
· Month 5
Detection of positive urine toxicology tests collected from chart reviews. Values are positive or negative for controlled substances. Positive test the worse outcome
| Group | Value | 95% CI |
|---|---|---|
| Intervention Arm | 6 |
Sponsor's own description
SASH is a clinical trial feasibility study that will provide an intervention to improve Opioid Use Disorder (OUD), Quality of Life (QOL), and housing outcomes for homeless patients receiving Medication for Opiate Use Disorder (MOUD). The main questions of the study are does a $500 housing stipend for individuals on MOUD increase treatment retention, improved quality of life and prevent homelessness.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05803603
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Opioid-Related Disorders
Currently open trials in the same condition.
- NCT06810076 — Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care · NA · active not recruiting
- NCT06454903 — Developing a Smartphone Application to Support Veteran Opioid Use Disorder Treatment · NA · recruiting
- NCT06387290 — Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits · Phase 3 · recruiting
- NCT06023459 — Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR) · Phase 3 · active not recruiting
- NCT06001749 — Psilocybin in Cancer Pain Study · Phase 2 · recruiting
Other University of Maryland, Baltimore trials
Trials by the same sponsor.
- NCT07537413 — Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia · Phase 4 · not yet recruiting
- NCT07221799 — OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis · Phase 1 · not yet recruiting
- NCT07094672 — Development of an Opioid Withdrawal Clinical Outcome Assessment · not yet recruiting
- NCT06583239 — Hub-Based Engagement Navigator Service to Reduce CSC Disengagement · NA · not yet recruiting
- NCT07536412 — Decision Aid Efficacy in Low Risk Thyroid Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05803603 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Maryland, Baltimore
- Last refreshed: 18 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05803603.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing